www.finanznachrichten.de ·
68275485 f hoffmann la roche ltd roche reports strong sales growth of 6 at constant exchange rates in the first quarter of 2026 5 in chf due to the sign 399
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedRoche's strong constant-exchange-rate sales growth highlights resilience in the healthcare sector despite currency headwinds. The performance reflects sustained demand for innovative medicines and diagnostics, supporting the broader pharmaceutical industry's outlook amid global economic uncertainties.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Roche reported 6% sales growth at CER in Q1 2026, reaching CHF 14.7 billion.
- Pharmaceuticals Division grew 7% at CER, Diagnostics Division grew 3% at CER.
- Key growth drivers: Xolair, Phesgo, Hemlibra, Vabysmo, Ocrevus generated CHF 5.3 billion.
- Reported sales in CHF declined 5% due to currency effects.
- Roche confirmed 2026 outlook: mid-single-digit sales growth, high single-digit core EPS growth.
Roche's strong Q1 2026 CER growth supports positive sentiment for the healthcare sector in the short term. However, the reliance on a single company's performance may not reflect broader sector dynamics.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- SP500_HEALTHCAREmid
- SP500_HEALTHCAREshort